Gagnon Advisors buys $1,038,777 stake in Neovasc Inc (US) (NVCN)

Neovasc Inc (US) (NVCN) : Gagnon Advisors scooped up 597,906 additional shares in Neovasc Inc (US) during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 1,892,125 shares of Neovasc Inc (US) which is valued at $1,038,777.Neovasc Inc (US) makes up approximately 0.83% of Gagnon Advisors’s portfolio.

Other Hedge Funds, Including , Gagnon Securities boosted its stake in NVCN in the latest quarter, The investment management firm added 375,243 additional shares and now holds a total of 2,431,837 shares of Neovasc Inc (US) which is valued at $1,335,079. Neovasc Inc (US) makes up approx 0.59% of Gagnon Securities’s portfolio. Denver Investment Advisors sold out all of its stake in NVCN during the most recent quarter. The investment firm sold 14,022 shares of NVCN which is valued $8,133. Geduld E E added NVCN to its portfolio by purchasing 150,000 company shares during the most recent quarter which is valued at $87,000. Neovasc Inc (US) makes up approx 0.12% of Geduld E E’s portfolio.

Neovasc Inc (US) opened for trading at $0.58 and hit $0.597 on the upside on Friday, eventually ending the session at $0.582, with a gain of 2.70% or 0.0153 points. The heightened volatility saw the trading volume jump to 7,04,893 shares. Company has a market cap of $39 M.

Many Wall Street Analysts have commented on Neovasc Inc (US). Neovasc Inc (US) was Downgraded by Ladenburg Thalmann to ” Neutral” on May 20, 2016.

Neovasc Inc. is a specialty medical device company. The Company develops manufactures and markets products for the cardiovascular marketplace. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease the Reducer for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. Its Tiara is a product for treating mitral valve disease. The Tiara is in preclinical/early clinical stage development to provide an invasive transcatheter device. The Tiara valve is made up of two components: the leaflets and skirt. It produces Peripatch a biological tissue product that is manufactured from pericardium which is the protective sac that surrounds the heart of an animal. It provides product development and specialized manufacturing services related to Peripatch tissue-based products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Neovasc Inc (US) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Neovasc Inc (US). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.